MX2020001146A - Analogos de carbamoil fenilalaninol y usos de los mismos. - Google Patents
Analogos de carbamoil fenilalaninol y usos de los mismos.Info
- Publication number
- MX2020001146A MX2020001146A MX2020001146A MX2020001146A MX2020001146A MX 2020001146 A MX2020001146 A MX 2020001146A MX 2020001146 A MX2020001146 A MX 2020001146A MX 2020001146 A MX2020001146 A MX 2020001146A MX 2020001146 A MX2020001146 A MX 2020001146A
- Authority
- MX
- Mexico
- Prior art keywords
- analogs
- phenylalaninol
- carbamoyl
- carbamoyl phenylalaninol
- methods
- Prior art date
Links
- NJVZDURTFWBXAM-VIFPVBQESA-N [(2S)-1-hydroxy-3-phenylpropan-2-yl]urea Chemical class C(N)(=O)N[C@@H](CC1=CC=CC=C1)CO NJVZDURTFWBXAM-VIFPVBQESA-N 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539088P | 2017-07-31 | 2017-07-31 | |
| PCT/US2018/044465 WO2019027941A1 (en) | 2017-07-31 | 2018-07-31 | CARBAMOYL PHENYLALANINOL ANALOGUES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001146A true MX2020001146A (es) | 2020-08-20 |
Family
ID=65233074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001146A MX2020001146A (es) | 2017-07-31 | 2018-07-31 | Analogos de carbamoil fenilalaninol y usos de los mismos. |
| MX2023005484A MX2023005484A (es) | 2017-07-31 | 2020-01-29 | Analogos de carbamoil fenilalaninol y usos de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005484A MX2023005484A (es) | 2017-07-31 | 2020-01-29 | Analogos de carbamoil fenilalaninol y usos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11413264B2 (enExample) |
| EP (1) | EP3661911A4 (enExample) |
| JP (2) | JP7366002B2 (enExample) |
| KR (1) | KR102643275B1 (enExample) |
| CN (1) | CN111094238B (enExample) |
| AU (1) | AU2018312328B2 (enExample) |
| CA (1) | CA3071779A1 (enExample) |
| MX (2) | MX2020001146A (enExample) |
| RU (1) | RU2020108634A (enExample) |
| SA (1) | SA520411187B1 (enExample) |
| SG (1) | SG11202000817SA (enExample) |
| WO (1) | WO2019027941A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| RU2020108634A (ru) * | 2017-07-31 | 2021-09-02 | Джаз Фармасьютикалз Айрлэнд Лимитед | Аналоги карбамоилфенилаланинола и способы их применения |
| AU2020231916B2 (en) | 2019-03-01 | 2025-08-28 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| EP4531833A2 (en) * | 2022-06-03 | 2025-04-09 | Axsome Therapeutics | Carbamoyl phenylalaninol compounds as taar1 agonists |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2604434B1 (fr) * | 1986-09-29 | 1989-05-19 | Inst Nat Sante Rech Med | Derives d'amino-2 ethanethiol, leur preparation et leur application en therapeutique |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| CA2240060C (en) * | 1996-10-10 | 2007-07-17 | Sk Corporation | O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same |
| AU4674797A (en) * | 1996-10-22 | 1998-05-15 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| US5935997A (en) * | 1998-01-13 | 1999-08-10 | Yukong Limited | O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically useful salts and process for preparing the same |
| JP4374441B2 (ja) | 1998-12-23 | 2009-12-02 | ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー | 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤 |
| US7553969B1 (en) * | 1999-01-28 | 2009-06-30 | Chugai Seiyaku Kabushiki Kaisha | Substituted phenethylamine derivatives |
| CN1160329C (zh) * | 1999-02-05 | 2004-08-04 | Sk株式会社 | O-硫代氨基甲酰基-氨基烷醇化合物,其药学上认可的盐及其制备方法 |
| WO2000064865A1 (en) * | 1999-04-23 | 2000-11-02 | Solvay Pharmaceuticals B.V. | Monomers and oligourea peptidomimetics and process for the prepa ration thereof |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| EP1264814A1 (en) * | 2001-06-08 | 2002-12-11 | Avantium International B.V. | Resolving agents based on amines |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| KR100576372B1 (ko) * | 2001-08-03 | 2006-05-03 | 에스케이 주식회사 | Ｏ-티오카바모일-아미노알카놀 화합물, 이의 약학적 허용염 및 제조방법 |
| ITFI20030113A1 (it) * | 2003-04-24 | 2004-10-25 | Menarini Ricerche Spa | Composti lineari nk-2 antagonisti con caratteristiche basiche e formulazioni che li contengono. |
| WO2006050037A1 (en) | 2004-10-28 | 2006-05-11 | Sk Corporation | Adjunctive therapy for depression |
| PL1890684T3 (pl) * | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
| ATE459393T1 (de) | 2005-06-22 | 2010-03-15 | Sk Holdings Co Ltd | Behandlung der sexuellen dysfunktion |
| CN101823987B (zh) * | 2009-03-06 | 2014-06-04 | 中国科学院上海药物研究所 | 一类新的dpp-ⅳ抑制剂及其制备方法和用途 |
| WO2011005473A2 (en) | 2009-06-22 | 2011-01-13 | Shionogi Pharma, Inc. | Methods for treating or preventing fatigue |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| RU2557533C2 (ru) | 2009-11-06 | 2015-07-20 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома фибромиалгии |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| CN102249833B (zh) * | 2011-05-27 | 2013-12-11 | 中国科学院化学研究所 | 一种制备手性γ-氨基酸及其衍生物的方法 |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| BR112015022197B1 (pt) | 2013-03-13 | 2022-06-07 | Sk Biopharmaceuticals Co., Ltd. | Uso de um composto para o tratamento de cataplexia |
| US20150018414A1 (en) | 2013-07-12 | 2015-01-15 | Jazz Pharmaceuticals International lll Limited | Promotion of Smoking Cessation |
| CN105873576B (zh) | 2013-07-18 | 2019-07-19 | 爵士制药国际Iii有限公司 | 治疗肥胖 |
| US10702498B2 (en) * | 2015-07-09 | 2020-07-07 | The Regents Of The University Of California | MU opioid receptor modulators |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| SG11201903076QA (en) | 2016-10-06 | 2019-05-30 | Jazz Pharmaceuticals International Iii Ltd | Carbamoyl phenylalaninol compounds and uses therof |
| RU2020108634A (ru) | 2017-07-31 | 2021-09-02 | Джаз Фармасьютикалз Айрлэнд Лимитед | Аналоги карбамоилфенилаланинола и способы их применения |
-
2018
- 2018-07-31 RU RU2020108634A patent/RU2020108634A/ru unknown
- 2018-07-31 AU AU2018312328A patent/AU2018312328B2/en active Active
- 2018-07-31 EP EP18840981.7A patent/EP3661911A4/en active Pending
- 2018-07-31 SG SG11202000817SA patent/SG11202000817SA/en unknown
- 2018-07-31 WO PCT/US2018/044465 patent/WO2019027941A1/en not_active Ceased
- 2018-07-31 CN CN201880059970.5A patent/CN111094238B/zh active Active
- 2018-07-31 CA CA3071779A patent/CA3071779A1/en active Pending
- 2018-07-31 KR KR1020207005652A patent/KR102643275B1/ko active Active
- 2018-07-31 JP JP2020505344A patent/JP7366002B2/ja active Active
- 2018-07-31 MX MX2020001146A patent/MX2020001146A/es unknown
- 2018-07-31 US US16/634,935 patent/US11413264B2/en active Active
-
2020
- 2020-01-29 MX MX2023005484A patent/MX2023005484A/es unknown
- 2020-01-29 SA SA520411187A patent/SA520411187B1/ar unknown
-
2022
- 2022-06-16 US US17/841,976 patent/US20220401401A1/en not_active Abandoned
-
2023
- 2023-04-26 JP JP2023072520A patent/JP7642707B2/ja active Active
-
2024
- 2024-09-30 US US18/901,040 patent/US20250017890A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210093603A1 (en) | 2021-04-01 |
| CN111094238A (zh) | 2020-05-01 |
| US11413264B2 (en) | 2022-08-16 |
| JP2023100758A (ja) | 2023-07-19 |
| WO2019027941A1 (en) | 2019-02-07 |
| RU2020108634A (ru) | 2021-09-02 |
| SG11202000817SA (en) | 2020-02-27 |
| US20220401401A1 (en) | 2022-12-22 |
| NZ762140A (en) | 2024-11-29 |
| AU2018312328B2 (en) | 2022-12-15 |
| EP3661911A4 (en) | 2021-04-14 |
| CA3071779A1 (en) | 2019-02-07 |
| MX2023005484A (es) | 2023-05-18 |
| AU2018312328A1 (en) | 2020-03-19 |
| JP7366002B2 (ja) | 2023-10-20 |
| JP7642707B2 (ja) | 2025-03-10 |
| JP2020530837A (ja) | 2020-10-29 |
| RU2020108634A3 (enExample) | 2021-11-30 |
| US20250017890A1 (en) | 2025-01-16 |
| KR20200045489A (ko) | 2020-05-04 |
| KR102643275B1 (ko) | 2024-03-04 |
| CN111094238B (zh) | 2023-06-09 |
| EP3661911A1 (en) | 2020-06-10 |
| SA520411187B1 (ar) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520411187B1 (ar) | نظائر فينيل ألانينول كربامويل واستخداماتها | |
| PH12019500751A1 (en) | Carbamoyl phenylalaninol compounds and uses thereof | |
| PH12019500494A1 (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| CA3024448C (en) | Modulatory polynucleotides | |
| EA201790806A1 (ru) | Иммунорегулирующие средства | |
| EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| MX381640B (es) | Metodos y compuestos agonistas de gip. | |
| MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| PH12020550871A1 (en) | Process for the preparation of opicapone and intermediates thereof | |
| MX2020003400A (es) | Profarmacos de dantroleno y metodos de su uso. | |
| MX2020005707A (es) | Profarmacos de creatina, composiciones y metodos de uso de estos. | |
| MX2020002147A (es) | Composiciones útiles para la mejora del dolor. | |
| GEP201706795B (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| ZA202105101B (en) | Peptides for treatment and prevention of diabetes and associated disorders |